Global Top 100 Players in 2017

The Global Top 100 Medtech companies comprise today of 83 Firms realizing a revenue above USD +1.0bn. Their growth was astonishingly generating USD 445.2bn in revenues in FY 2017 (+6.3% growth Y-T-Y). We compared their joined performance against 2016, 2015, 2014 and 2013 in order to gain an updated insight on: 

  • Who are the Global Top 100 of 2017?
  • Who are the outliers in FY 2017?
  • Which challenges affected companies most?
  • Which cohort (in groupings of 20 companies) achieve an ideal performance? 
  • Which growth strategy (organic/ mixed/ pure M&A-driven approach) worked best last year?
  • Where do the Global Top 100 invest and play?


If you are interested in a further deep-dive discussion on this subject, please feel free to contact us at your convenience:

Yes, I would like to learn more on growth potentials applying Insight in Best Practices of Medtech leaders  - please contact us 

In a Nutshell:

"Global Top100 facing an era of market consolidation to slow to moderate growth"

International ranking of the Global Top 100 Medtech companies in 2017
(Revenues in USD bn):

  • The Global Top 100 firms companies achieved a Y-T-Y growth of 6.3% totaling USD 445.2bn
  • Average bottom-line Y-T-Y growth was positive, down by -3.2% to +15.1% in FY 2017
  • They currently employ 1.56m employees worldwide, representing an increase of -4.8% over 1.64m employees in 2016

  • Noteworthy is the decline in R&D spending since 2014, falling from 7.5% to 6.9% in 2017
  • Most Top 100 companies’ outlook is positive with single-digit growth expected

  • ....